

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 August 2018 (16.08.2018)



(10) International Publication Number
WO 2018/145627 A1

(51) International Patent Classification:
C12Q 1/68 (2018.01)

(21) International Application Number:
PCT/CN2018/075474

(22) International Filing Date:
06 February 2018 (06.02.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/456,087 07 February 2017 (07.02.2017) US

(71) Applicant: **TCM BIOTECH INTERNATIONAL CORP.** [CN/CN]; 24F.-8, No.97, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City, Taiwan 22175 (CN).

(72) Inventors: **LIN, You-Yu**; National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei

City, Taiwan 10002 (CN). **WANG, Ya-Chun**; 24F.-8, No.97, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City, Taiwan 22175 (CN). **TZENG, Sheng-Tai**; 24F.-8, No.97, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City, Taiwan 22175 (CN).

(74) Agent: **SHENZHEN SCIENBIZIP INTELLECTUAL PROPERTY AGENCY CO., LTD.**; 9F, Rongqun Building, No.83 Longguan East Rd., Longhua New Dist., Shenzhen, Guangdong 518109 (CN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: PROBE COMBINATION FOR DETECTION OF CANCER




FIG. 2B

(57) Abstract: A probe combination for detecting cancer includes one or more sets of partial hepatitis B virus (HBV) targeting probes. When sequences of each of the sets of partial HBV targeting probes are aligned, an overall sequence of the aligned set of probes matches a reference sequence of a genome of a HBV genotype or a direct repeat (DR) region on the genome. In the aligned set of probes, each of the probes overlap with one or two adjacent probes by a portion of a length of the probe. The probe combination may further includes one or more sets of hotspot gene targeting probes targeting cancer hotspot genes such as CTNNB1, TERT, and TP53 genes, one or more sets of exogenous gene targeting probes targeting portions of a lambda phage genome, and endogenous gene targeting probes targeting endogenous genes such as GAPDH and GdX genes.

[Continued on next page]



WO 2018/145627 A1

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))